Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

888
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
888
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

400
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
400
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

572
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
572
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

645
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
645
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

3.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.2K
Ligand-gated Ion Channels01:19

Ligand-gated Ion Channels

13.4K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report.

Pharmacotherapy·2026
Same author

Development and Validation of Pharmacology Concept Inventory for Concept-Based Learning: Leveraging Theory, Expert Insights, and Student Perspectives.

Pharmacology research & perspectives·2026
Same author

Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non-Prescription Drug Assessment Unit.

British journal of clinical pharmacology·2025
Same author

Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning.

Cellular and molecular life sciences : CMLS·2025
Same author

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database.

British journal of clinical pharmacology·2025
Same author

Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Nov 6, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K

Do gabapentin or pregabalin directly modulate the µ receptor?

Preeti Manandhar1, Bridin Patricia Murnion2,3, Natasha L Grimsey4

  • 1Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.

Peerj
|May 6, 2021
PubMed
Summary

Pregabalin and gabapentin do not directly affect the mu-opioid receptor. These drugs do not augment morphine

Keywords:
GabapentinGabapentinoidsMorphineOpioidOpioid receptor signalingOpioid-related harmOverdosePregabalinµ receptor

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.3K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.7K

Related Experiment Videos

Last Updated: Nov 6, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.3K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.7K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Molecular Biology

Background:

  • Pregabalin and gabapentin are used for neuropathic pain but concerns exist about misuse, especially with opioids.
  • Co-ingestion of gabapentinoids with opioids is linked to increased opioid-related deaths.
  • The molecular mechanisms underlying these enhanced risks are not fully understood.

Purpose of the Study:

  • To investigate if pregabalin or gabapentin directly modulate mu-opioid receptor signaling.
  • To determine if these drugs affect morphine's activation of the mu-opioid receptor.

Main Methods:

  • HEK 293 cells expressing human mu-receptors were used to assess pregabalin/gabapentin effects on morphine-induced responses.
  • Assays included membrane potential, cAMP production, and ERK phosphorylation.
  • Effects on morphine-induced hyperpolarization were also studied in AtT20 cells.

Main Results:

  • Pregabalin and gabapentin did not activate the mu-opioid receptor or alter morphine's effects on K+ channel activation or ERK phosphorylation.
  • Neither drug affected morphine-induced receptor desensitization.
  • High-concentration pregabalin (100 µM) increased cAMP production independently of morphine.

Conclusions:

  • Data do not support direct or allosteric modulation of the mu-opioid receptor by pregabalin or gabapentin.
  • The findings do not explain how these drugs might augment opioid effects.
  • Further research is needed to understand the mechanisms behind increased opioid-related harms with co-ingestion.